Evidence map›Paper›PMID 36178743›Full record

ArticleCirculation. Arrhythmia and electrophysiology2022

Targeting the RyR2 to Prevent Atrial Fibrillation.

Anne M Gillis, Dobromir Dobrev

Abstract readEditorialComment
In one paragraph

Article in Circulation. Arrhythmia and electrophysiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. The Role ofCase reports in cardiology · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Anne M GillisDepartment of Cardiac Sciences, University of Calgary and Libin Cardiovascular Institute, Alberta, Canada (A.M.G.).ORCID 0000-0001-9591-4291
Dobromir DobrevInstitute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Germany (D.D.).ORCID 0000-0002-4612-117X

Funding

Ryanodine receptor regulation in post-operative atrial fibrillationR01HL089598 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI WEHRENS, XANDER H.T. · 2007 to 2022
$6.5M
The Role of Inflammasome in the Pathogenesis of Atrial FibrillationR01HL136389 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI Na Li · 2017 to 2026
$5.6M
Sex-specific arrhythmogenic mechanisms of atrial fibrillationR01HL131517 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Eleonora Grandi · 2016 to 2026
$5.0M
Cardiac fibroblast inflammasome and atrial myopathyR01HL163277 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI LI, NA · 2022 to 2025
$2.8M
NHLBI NIH HHS R01 HL089598NHLBI NIH HHS R01 HL131517NHLBI NIH HHS R01 HL136389NHLBI NIH HHS R01 HL163277
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Atrial FibrillationRyanodine Receptor Calcium Release ChannelAnti-Arrhythmia AgentsCalciumHumansSarcoplasmic ReticulumAnti-Arrhythmia AgentsCalciumRyanodine Receptor Calcium Release Channelantiarrhythmic drugsatrial fibrillationEditorialsmorbidityrisksarcoplasmic reticulum

Identifiers

PMID36178743
PMCPMC9592734

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.